Codexis (CDXS) 10-Q 5 Nov 21 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2021	Nov. 01, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-34705
Entity Registrant Name	Codexis, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	71-0872999
Entity Address, Address Line One	200 Penobscot Drive
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94063
City Area Code	650
Local Phone Number	421-8100
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	CDXS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		64,875,278
Entity Central Index Key	0001200375
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 119,189,000	$ 149,117,000
Restricted cash, current	581,000	638,000
Investment in non-marketable debt security	0	1,000,000
Financial assets:
Accounts receivable	25,084,000	13,894,000
Contract assets	12,701,000	4,526,000
Unbilled receivables	10,760,000	10,942,000
Total financial assets	48,545,000	29,362,000
Less: allowances	(74,000)	(74,000)
Total financial assets, net	48,471,000	29,288,000
Inventories	1,084,000	964,000
Prepaid expenses and other current assets	4,787,000	3,416,000
Total current assets	174,112,000	184,423,000
Restricted cash	1,519,000	1,062,000
Investment in non-marketable equity securities	12,763,000	1,450,000
Right-of-use assets - Operating leases, net	19,478,000	21,382,000
Right-of-use assets - Finance leases, net	43,000	119,000
Property and equipment, net	16,124,000	9,675,000
Goodwill	3,241,000	3,241,000
Other non-current assets	271,000	294,000
Total assets	227,551,000	221,646,000
Current liabilities:
Accounts payable	3,281,000	2,970,000
Accrued compensation	9,041,000	7,288,000
Other accrued liabilities	15,927,000	10,272,000
Current portion of lease obligations - Operating leases	2,782,000	2,627,000
Deferred revenue	2,449,000	1,824,000
Total current liabilities	33,480,000	24,981,000
Deferred revenue, net of current portion	3,747,000	2,967,000
Long-term lease obligations - Operating leases	20,218,000	22,324,000
Other long-term liabilities	1,051,000	1,271,000
Total liabilities	58,496,000	51,543,000
Commitments and Contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.0001 par value per share; 100,000 shares authorized; 64,833 and 64,283 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	6,000	6,000
Additional paid-in capital	546,557,000	536,516,000
Accumulated deficit	(377,508,000)	(366,419,000)
Total stockholders' equity	169,055,000	170,103,000
Total liabilities and stockholders' equity	$ 227,551,000	$ 221,646,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	64,833,000	64,283,000
Common stock, shares outstanding (in shares)	64,833,000	64,283,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues:
Total revenues	$ 36,769	$ 18,385	$ 80,253	$ 48,023
Costs and operating expenses:
Cost of product revenue	6,867	3,642	15,403	7,882
Research and development	15,165	12,010	39,562	33,830
Selling, general and administrative	13,407	8,797	37,600	26,307
Total costs and operating expenses	35,439	24,449	92,565	68,019
Income (loss) from operations	1,330	(6,064)	(12,312)	(19,996)
Interest income	41	39	424	362
Other income (expense), net	983	(50)	920	(125)
Income (loss) before income taxes	2,354	(6,075)	(10,968)	(19,759)
Provision for income taxes	110	19	121	331
Net income (loss)	$ 2,244	$ (6,094)	$ (11,089)	$ (20,090)
Net income (loss) per share, basic (in usd per share)	$ 0.03	$ (0.10)	$ (0.17)	$ (0.34)
Net income (loss) per share, diluted (in usd per share)	$ 0.03	$ (0.10)	$ (0.17)	$ (0.34)
Weighted average common stock shares used in computing net income (loss) per share, basic (in shares)	64,628	59,061	64,452	58,984
Weighted average common stock shares used in computing net income (loss) per share, diluted (in shares)	67,741	59,061	64,452	58,984
Product revenue
Revenues:
Total revenues	$ 28,731	$ 8,401	$ 53,674	$ 18,005
Research and development revenue
Revenues:
Total revenues	$ 8,038	$ 9,984	$ 26,579	$ 30,018

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Employee	Nonemployee	Common Stock	Additional paid-in Capital	Additional paid-in CapitalEmployee	Additional paid-in CapitalNonemployee	Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2019				58,877,000
Balance at beginning of period at Dec. 31, 2019	$ 105,517			$ 6	$ 447,920			$ (342,409)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	87,240			87,000
Exercise of stock options	$ 539				539
Release of stock awards (in shares)				370,000
Taxes paid related to net shares settlement of equity awards (in shares)				(102,000)
Taxes paid related to net shares settlement of equity awards	(1,257)				(1,257)
Employee stock-based compensation		$ 6,045	$ 47			$ 6,045	$ 47
Net income (loss)	(20,090)							(20,090)
Balance at end of period (in shares) at Sep. 30, 2020				59,232,000
Balance at end of period at Sep. 30, 2020	90,801			$ 6	453,294			(362,499)
Balance at beginning of period (in shares) at Jun. 30, 2020				59,125,000
Balance at beginning of period at Jun. 30, 2020	94,786			$ 6	451,185			(356,405)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)				55,000
Exercise of stock options	342				342
Release of stock awards (in shares)				70,000
Taxes paid related to net shares settlement of equity awards (in shares)				(18,000)
Taxes paid related to net shares settlement of equity awards	(217)				(217)
Employee stock-based compensation		1,941	43			1,941	43
Net income (loss)	(6,094)							(6,094)
Balance at end of period (in shares) at Sep. 30, 2020				59,232,000
Balance at end of period at Sep. 30, 2020	90,801			$ 6	453,294			(362,499)
Balance at beginning of period (in shares) at Dec. 31, 2020				64,283,000
Balance at beginning of period at Dec. 31, 2020	$ 170,103			$ 6	536,516			(366,419)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	422,964			423,000
Exercise of stock options	$ 2,700				2,700
Release of stock awards (in shares)				181,000
Taxes paid related to net shares settlement of equity awards (in shares)				(54,000)
Taxes paid related to net shares settlement of equity awards	(1,206)				(1,206)
Employee stock-based compensation		8,360	187			8,360	187
Net income (loss)	(11,089)							(11,089)
Balance at end of period (in shares) at Sep. 30, 2021				64,833,000
Balance at end of period at Sep. 30, 2021	169,055			$ 6	546,557			(377,508)
Balance at beginning of period (in shares) at Jun. 30, 2021				64,623,000
Balance at beginning of period at Jun. 30, 2021	162,773			$ 6	542,519			(379,752)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)				210,000
Exercise of stock options	1,022				1,022
Employee stock-based compensation		$ 2,955	$ 61			$ 2,955	$ 61
Net income (loss)	2,244							2,244
Balance at end of period (in shares) at Sep. 30, 2021				64,833,000
Balance at end of period at Sep. 30, 2021	$ 169,055			$ 6	$ 546,557			$ (377,508)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities:
Net loss	$ (11,089)	$ (20,090)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2,143	1,403
Amortization expense - right-of-use assets - operating and finance leases	1,980	1,964
Stock-based compensation	8,547	6,092
Allowance for credit losses	0	40
Equity securities earned from research and development activities	(675)	0
Unrealized gain on non-marketable securities	(1,033)	0
Other non-cash items	(19)	0
Changes in operating assets and liabilities:
Financial assets, net	(19,633)	(6,482)
Inventories	(120)	(366)
Prepaid expenses and other assets	(1,195)	(1,105)
Accounts payable	575	(101)
Accrued compensation and other accrued liabilities	7,036	3,581
Other long-term liabilities	(2,324)	(1,920)
Deferred revenue	880	2,012
Net cash used in operating activities	(14,927)	(14,972)
Investing activities:
Purchase of property and equipment	(8,348)	(2,260)
Proceeds from sale of property and equipment	36	0
Investment in equity securities	(7,630)	(1,000)
Net cash used in investing activities	(15,942)	(3,260)
Financing activities:
Proceeds from exercises of stock options	2,700	539
Costs incurred in connection with equity financing	(153)	0
Payments of lease obligations - Finance leases	0	(60)
Taxes paid related to net share settlement of equity awards	(1,206)	(1,257)
Net cash provided by (used in) financing activities	1,341	(778)
Net decrease in cash, cash equivalents and restricted cash	(29,528)	(19,010)
Cash, cash equivalents and restricted cash at the beginning of the period	150,817	92,221
Cash, cash equivalents and restricted cash at the end of the period	121,289	73,211
Supplemental disclosure of cash flow information:
Interest paid	6	15
Income taxes paid	101	312
Capital expenditures incurred but not yet paid	2,012	289
Cash reconciliation:
Cash and cash equivalents	119,189	71,516
Restricted cash, current and non-current	2,100	1,695
Total cash, cash equivalents and restricted cash	$ 121,289	$ 73,211

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business In these notes to the unaudited condensed consolidated financial statements, the “Company,” “we,” “us,” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis. We discover, develop and sell enzymes and other proteins that deliver value to our clients in a growing set of industries to commercialize an increasing number of novel enzymes, both as proprietary Codexis products and in partnership with our customers. We are a pioneer in harnessing computational technologies to drive biology advancements. Since 2002, we have made substantial investments in the development of our CodeEvolver ® protein engineering technology platform. Our technology platform is powered by proprietary, artificial intelligence-based, computational algorithms that rapidly mine the structural and performance attributes of our large and continuously growing library of protein variants. These computational outputs enable increasingly reliable predictions for next generation protein variants to be engineered, enabling time- and cost-efficient delivery of the targeted performance enhancements. Additionally, our CodeEvolver ® protein engineering technology platform integrates additional modular competencies, including robotic high-throughput screening and genomic sequencing, organic chemistry and bioprocess development which are all coordinated to rapidly innovate novel, fit-for-purpose products. The core historical application of the technology has been in developing commercially viable biocatalytic manufacturing processes for more sustainable production of complex chemicals. This begins by conceptually designing the most cost-effective and practical process for a targeted product. We then develop optimized biocatalysts to enable the designed process, using our CodeEvolver ® platform. Engineered biocatalyst candidates, numbering many thousands for each project, are then rapidly screened and validated using high throughput methods under process-relevant operating conditions. This approach results in an optimized biocatalyst that enables cost-efficient processes that are relatively simple to run in conventional manufacturing equipment. This also allows for efficient technical transfer of our processes to our manufacturing partners. We initially commercialized our CodeEvolver ® protein engineering technology platform and products in the manufacture of small molecule pharmaceuticals, which remains a primary business focus. Our customers, which include many large, global pharmaceutical companies, use our technology, products and services in their process development and in manufacturing. Additionally, we have licensed our proprietary CodeEvolver ® protein engineering technology platform to global pharmaceutical companies enabling them to use this technology, in house, to engineer enzymes for their own businesses. Most recently, in May 2019, we entered into a Platform Technology Transfer and License Agreement (the “Novartis CodeEvolver ® Agreement”) with Novartis. The Novartis CodeEvolver ® Agreement (our third such agreement with large pharma companies) allows Novartis to use our proprietary CodeEvolver ® protein engineering platform technology in the field of human healthcare. As evidence of our strategy to extend our technology beyond pharmaceutical manufacturing, we have also used the technology to develop biocatalysts and enzyme products for use in a broader set of industrial markets, including several large verticals, such as food, feed, consumer care and fine chemicals. In addition, we are using our technology to develop enzymes for various life science related applications, such as next generation sequencing (“NGS”) and polymerase chain reaction (“PCR/qPCR”) for in vitro molecular diagnostic and genomic research applications. In December 2019, we entered into a license agreement to provide Roche Sequencing Solutions, Inc. with our first enzyme for this target market: the Company’s EvoT4™ DNA ligase. In June 2020, we entered into a co-marketing and enzyme supply collaboration agreement with Alphazyme LLC for the production and co-marketing of enzymes for life science applications including, initially, high-fidelity DNA polymerase, T7 RNA polymerase and reverse transcriptase enzymes. We have been using the CodeEvolver ® protein engineering technology platform to develop early stage, novel biotherapeutic product candidates, both in partnership with customers and for our own proprietary Codexis drug candidates. Our first program was for the potential treatment of phenylketonuria ("PKU") in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we entered into a Global Development, Option and License Agreement (the “Nestlé License Agreement”) with Société des Produits Nestlé S.A., formerly known as Nestec Ltd. (“Nestlé Health Science”) to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of PKU. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive license to develop and commercialize CDX-6114. Also in October 2017, we entered into a strategic collaboration agreement with Nestlé Health Science (“Nestlé SCA”) pursuant to which we and Nestlé Health Science are collaborating to leverage the CodeEvolver ® platform technology to develop other novel enzymes for Nestlé Health Science’s established Consumer Care and Medical Nutrition business areas. In January 2020, we entered into a development agreement with Nestlé Health Science to advance a new lead candidate discovered under the Nestlé SCA, CDX-7108, into preclinical development and early clinical studies as a potential treatment for a gastrointestinal disorder. In March 2020, we entered into a Strategic Collaboration and License Agreement (“Takeda Agreement”) with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”), for the research and development of novel gene therapies for certain disease indications, including the treatment of lysosomal storage disorders and a blood factor deficiency. In June 2020, we entered into a Master Collaboration and Research Agreement (the “MAI Agreement”) with Molecular Assemblies, Inc ("MAI") pursuant to which we are leveraging our CodeEvolver ® platform technology to improve the DNA polymerase enzymes that are critical for enzymatic DNA synthesis. Concurrently with the MAI Agreement, we purchased 1,587,050 shares of MAI's Series A preferred stock for $1.0 million and, in connection with the transaction, John Nicols, our President and Chief Executive Officer, joined MAI’s board of directors. In April 2021, we purchased an additional 1,000,000 shares of MAI's Series A preferred stock for $0.6 million. In September 2021, we purchased 9,198,423 shares of MAI's Series B preferred stock for $7.0 million (see Note 11 "Related Party Transactions" for additional information). See Note 12 "Segment, Geographical and Other Revenue Information" for additional information. Below are brief descriptions of our business segments: Performance Enzymes We initially commercialized our CodeEvolver ® protein engineering technology platform and products in the manufacture of small molecule pharmaceuticals and, to date, this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food, feed, consumer care, and fine chemicals. We also use our technology in the life sciences markets to develop enzymes for customers using NGS and PCR/qPCR for in vitro molecular diagnostic and molecular biology research applications, as well DNA/RNA synthesis and health monitoring applications. Novel Biotherapeutics We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver ® protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Our first lead program was for the potential treatment of PKU in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we announced a global development, option and license agreement with Nestlé Health Science to advance CDX-6114, our own novel orally administrable enzyme therapeutic candidate for the potential treatment of PKU. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. Upon exercising its option, Nestlé Health Science assumed all responsibilities for future clinical development and commercialization of CDX-6114. In October 2017, we entered into the Nestlé SCA pursuant to which we and Nestlé Health Science are collaborating to leverage the CodeEvolver ® platform technology to develop other novel enzymes for Nestlé Health Science’s established Consumer Care and Medical Nutrition business areas. The Nestlé SCA was extended through December 2021. In January 2020, we and Nestlé Health Science entered into a development agreement pursuant to which we and Nestlé Health Science are collaborating to advance into preclinical and early clinical studies a lead candidate targeting a gastrointestinal disorder, CDX-7108, discovered through the Nestlé SCA. During 2021, we, together with Nestlé Health Science, continued to advance CDX-7108 towards initiation of a Phase 1 clinical trial which commenced in October 2021. Additionally, the parties are progressing three programs under the Nestlé SCA targeting different gastrointestinal disorders. In March 2020, we entered into the Takeda Agreement pursuant to which we are collaborating to research and develop protein sequences for use in gene therapy products for certain disease indications in accordance with the respective program plans for Fabry Disease, Pompe Disease, and an undisclosed blood factor deficiency. In March 2020, we received a one-time, non-refundable cash payment of $8.5 million. Of these programs, the Fabry disease program is the most advanced, with multiple sequences, including CDX-6311, having been provided to Takeda. In May 2021, Takeda elected to exercise their option to expand the collaboration into a fourth program for an undisclosed rare genetic disorder. Business Update Regarding COVID-19 We are subject to risks and uncertainties as a result of the current COVID-19 pandemic. The COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, communities and business operations, as well as the U.S. economy and other economies worldwide. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and may not be accurately predicted, including the duration and severity of the pandemic and the extent and severity of the impact on our customers, new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets. To date, we and our collaboration partners have been able to continue to supply our enzymes to our customers worldwide. However, we are dependent on our manufacturing and logistics partners and consequently, disruptions in operations of our partners and customers may affect our ability to supply enzymes to our customers. Furthermore, our ability to provide future research and development ("R&D") services will continue to be impacted as a result of governmental orders and any disruptions in operations of our customers with whom we collaborate. We believe that these disruptions have had a minimal impact on revenue for the three and nine months ended September 30, 2021. The extent to which the pandemic may impact our business operations and operating results will continue to remain highly dependent on future developments, which are uncertain and cannot be predicted with confidence. In the U.S., the impact of COVID-19, including governmental orders ("Orders") governing the operation of businesses during the pandemic, caused the temporary closure of our Redwood City, California facilities and disrupted our R&D operations in 2020. R&D operations for several projects were temporarily suspended from mid-March 2020 through the end of April 2020 in accordance with these Orders. In May 2020, we initiated limited R&D operations and have ramped up operations such that we are currently utilizing our normal R&D capacity while following county, state and federal COVID-19 guidance for the protection of our employees. Additionally, we resumed manufacturing at our Redwood City pilot plant in May 2020.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying Unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information but does not include all the information and notes required by GAAP for complete financial statements. These interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2020. The condensed consolidated balance sheet at December 31, 2020, has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The significant accounting policies used in preparation of the Unaudited Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2021 and 2020, are consistent with those discussed in Note 2 to the audited consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K and are updated below as necessary. There have been no significant changes in our significant accounting policies or critical accounting estimates since December 31, 2020. Certain prior year amounts have been reclassified in the Unaudited Condensed Statements of Cash Flows to conform to the 2021 presentation, however these reclassifications had no effect on the reported results of operations. The Unaudited Condensed Consolidated Financial Statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly our financial position as of September 30, 2021, results of our operations for the three and nine months ended September 30, 2021 and 2020, changes in stockholders' equity for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020. The interim results are not necessarily indicative of the results for any future interim period or for the entire year. The Unaudited Condensed Consolidated Financial Statements include the accounts of Codexis, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, inventories, valuation of equity investments, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, and may not be accurately predicted, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers, markets and economies. Accounting Pronouncements Recently adopted accounting pronouncements In December 2019, the Financial Accounting Standards Board ("FASB") issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which is intended to simplify various aspects related to accounting for income taxes. We adopted the standard on January 1, 2021, on a modified retrospective basis. The adoption of this standard had no impact on our Unaudited Condensed Consolidated Financial Statements. In October 2020, the FASB issued ASU No. 2020-10, Codification Improvement s. ASU 2020-10 provides amendments to a wide variety of topics in the FASB’s Accounting Standards Codification, which applies to all reporting entities within the scope of the affected accounting guidance. We adopted the standard on January 1, 2021 on a retrospective basis. The adoption of this standard had no impact on our Unaudited Condensed Consolidated Financial Statements. Recently issued accounting pronouncements not yet adopted From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the recently issued standards that are not yet effective will not have a material impact on our Unaudited Condensed Consolidated Financial Statements upon adoption. In May 2021, FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the Emerging Issues Task Force . The standard establishes a principles-based framework in accounting for modifications of freestanding equity-classified written call options on the basis of the economic substance of the underlying transaction. The standard also requires incremental financial statement disclosures. The standard affects entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years with early adoption is permitted by applying the standard as of the beginning of the fiscal year that includes that interim period. The standard may be adopted prospectively for modifications or exchanges occurring on or after the effective date. We will evaluate modifications of equity-classified written call options to determine applicability of the standard on occurrence; however, we believe that the adoption of ASU 2021-04 will have no significant impact on our Unaudited Condensed Consolidated Financial Statements and related disclosures. In August 2020, FASB issued ASU No. 2020-06 Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40) No. 2020-06 August 2020 Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , to reduce the complexity and to simplify the accounting for convertible debt instruments and convertible preferred stock, and the derivatives scope exception for contracts in an entity's own equity. In addition, the guidance on calculating diluted earnings per share has been simplified and made more internally consistent. The standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years with early adoption permitted for fiscal years beginning December 15, 2020. The standard may be adopted on a modified retrospective or fully retrospective method of transition and on adoption, entities may irrevocably elect the fair value option in accordance with Subtopic 825-10, Financial Instruments—Overall, for any financial instrument that is a convertible security. We believe that the adoption of ASU 2020-06 will have no significant impact on our Unaudited Condensed Consolidated Financial Statements and related disclosures. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The standard provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions in which the reference LIBOR or another reference rate are expected to be discontinued as a result of the Reference Rate Reform. The standard is effective for all entities and can be adopted no later than December 1, 2022, with early adoption permitted. The standard may be adopted on a prospective basis. We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to elect optional expedients for contract modification; however, we believe that the adoption of ASU 2020-04 will have no significant impact on our Unaudited Condensed Consolidated Financial Statements and related disclosures. There have been no other recent accounting pronouncements or changes in accounting pronouncements during the three and nine months ended September 30, 2021, as compared to the recent accounting pronouncements described in herein, that are of significance or potential significance to us.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Disaggregation of Revenue The following table provides information about disaggregated revenue from contracts with customers into the nature of the products and services, and geographic regions, and includes a reconciliation of the disaggregated revenue with reportable segments. The geographic regions that are tracked are the Americas (United States, Canada, and Latin America), EMEA (Europe, Middle East, and Africa), and APAC (Australia, New Zealand, Southeast Asia, and China). Segment information is as follows (in thousands): Three months ended September 30, 2021 Three months ended September 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product revenue $ 28,731 $ — $ 28,731 $ 8,401 $ — $ 8,401 Research and development revenue 3,853 4,185 8,038 4,604 5,380 9,984 Total revenues $ 32,584 $ 4,185 $ 36,769 $ 13,005 $ 5,380 $ 18,385 Primary geographical markets: Americas $ 5,999 $ 1,817 $ 7,816 $ 3,209 $ 2,632 $ 5,841 EMEA 2,317 2,368 4,685 2,141 2,748 4,889 APAC 24,268 — 24,268 7,655 — 7,655 Total revenues $ 32,584 $ 4,185 $ 36,769 $ 13,005 $ 5,380 $ 18,385 Nine months ended September 30, 2021 Nine months ended September 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product revenue $ 53,674 $ — $ 53,674 $ 18,005 $ — $ 18,005 Research and development revenue 14,723 11,856 26,579 13,380 16,638 30,018 Total revenues $ 68,397 $ 11,856 $ 80,253 $ 31,385 $ 16,638 $ 48,023 Primary geographical markets: Americas $ 12,573 $ 6,015 $ 18,588 $ 7,381 $ 10,591 $ 17,972 EMEA 11,294 5,841 17,135 8,128 6,047 14,175 APAC 44,530 — 44,530 15,876 — 15,876 Total revenues $ 68,397 $ 11,856 $ 80,253 $ 31,385 $ 16,638 $ 48,023 Contract Balances The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands): September 30, 2021 December 31, 2020 Contract assets $ 12,701 $ 4,526 Unbilled receivables $ 10,760 $ 10,942 Contract costs $ 70 $ 90 Contract liabilities: deferred revenue $ 6,196 $ 4,791 We had no asset impairment charges related to financial assets in the three and nine months ended September 30, 2021 and 2020. The increase in contract assets was primarily due to increase in product revenue from contracts subject to over time revenue recognition. The nominal decrease in unbilled receivables was primarily due to the timing of billings. The increase in deferred revenue was primarily due to cash advances received in excess of revenue recognized. We recognized the following revenues (in thousands): Three months ended September 30, Nine months ended September 30, Revenue recognized in the period for: 2021 2020 2021 2020 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 658 $ 708 $ 1,997 $ 58 Changes in the period: Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods 1,521 233 5,848 854 Performance obligations satisfied from new activities in the period - contract revenue 34,590 17,444 72,408 47,111 Total revenues $ 36,769 $ 18,385 $ 80,253 $ 48,023 Performance Obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2021. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of September 30, 2021 (in thousands): Remainder of 2021 2022 2023 2024 and Thereafter Total Product revenue $ 5 $ 67 $ 67 $ 2,700 $ 2,839 Research and development revenue 1,106 1,705 546 — 3,357 Total revenues $ 1,111 $ 1,772 $ 613 $ 2,700 $ 6,196

Net Income (loss) per Share

Net Income (loss) per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Income (loss) per Share	N et Income (loss) per S hare Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding, less restricted stock awards (“RSAs”) subject to forfeiture. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock shares outstanding, less RSAs subject to forfeiture, plus all additional common shares that would have been outstanding, assuming dilutive potential common stock shares had been issued for other dilutive securities. Anti-Dilutive Securities In periods of net loss, the weighted average number of shares outstanding, prior to the application of the treasury stock method, excludes potentially dilutive securities from the computation of diluted net loss per common share because including such shares would have an anti-dilutive effect. The following table sets forth the computation of basic and diluted net income (loss) per share during the three and nine months ended September 30, 2021 and 2020 (in thousands, except per share amounts): Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Numerator: Net income (loss) $ 2,244 $ (6,094) $ (11,089) $ (20,090) Denominator: Weighted average common stock shares used in computing net income (loss) per share, basic 64,628 59,061 64,452 58,984 Effect of dilutive shares 3,113 — — — Weighted average common stock shares used in computing net income (loss) per share, diluted 67,741 59,061 64,452 58,984 Net income (loss) per share, basic $ 0.03 $ (0.10) $ (0.17) $ (0.34) Net income (loss) per share, diluted $ 0.03 $ (0.10) $ (0.17) $ (0.34) Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Shares issuable under the Equity Incentive Plan 451 5,182 5,148 5,182

Investments in Non-Marketable S

Investments in Non-Marketable Securities	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Investments in Non-Marketable Securities	Investments in Non-Marketable Securities Non-Marketable Debt Securities We classify non-marketable debt securities, which are accounted for as available-for-sale, within Level 3 in the fair value hierarchy because we estimate the fair value based on a qualitative analysis using the most recent observable transaction price and other significant unobservable inputs including volatility, rights, and obligations of the securities we hold. We determine gains or losses on the sale or extinguishment of non-marketable debt securities using a specific identification method. Unrealized gains and losses from bifurcated embedded derivatives, which represent share-settled redemption features, are recorded as other expense, net, in the unaudited condensed consolidated statements of operations. Unrealized gains and losses on non-marketable debt securities are recorded as a component of other comprehensive loss until realized. Realized gains or losses are recorded as a component of other income (expense), net. In November 2020, we purchased convertible subordinated notes issued by Arzeda Corp., an early-stage computational protein design company, for $1.0 million. The investment was classified as available-for-sale non-marketable interest-bearing debt securities with a carrying value of $1.0 million as of December 31, 2020. In July 2021, we converted the non-marketable debt security with a carrying value of $1.3 million into 207,070 shares of Series B-2 preferred stock of Arzeda Corp. In the three and nine months ended September 30, 2021, w e recognized nil and $0.3 million, respectively, in interest income from amortization of debt discount and interest earned on our investment in this debt security, and nil and $10.5 thousand in other expense , respectively, in other income (expense), net, on the change in the fair value of an embedded bifurcated derivative. We recognized no unrealized or realized gains or losses during the three and nine months ended September 30, 2021. We recognized no interest income, other expenses, and unrealized or realized gains or losses during the three and nine months ended September 30, 2020. There were no investments in non-marketable debt securities at September 30, 2021. As of December 31, 2020, the adjusted cost and carrying value and fair value of the non-marketable debt security is the following (in thousands): December 31, 2020 Adjusted Cost and Carrying Value Fair Value Non-marketable debt security due in 1 year or less $ 1,000 $ 1,000 Non-Marketable Equity Securities Non-marketable equity securities are investments in privately held companies without readily determinable market value. We measure investments in non-marketable equity securities without a readily determinable fair value using a measurement alternative that measures these securities at the cost method minus impairment, if any, plus or minus changes resulting from observable price changes on a non-recurring basis. We adjust the carrying value of non-marketable equity securities which have been remeasured during the period and recognize resulting gains or losses as a component of other income (expense), net. We measured our equity investments in MAI and Arzeda Corp. based on the measurement alternative and adjusted the carrying values for observable price changes in orderly transactions for an identical or similar equity securities of the same issuer. We recognized a $0.7 million gain in other income (expense), net, on the change in the carrying value of our investment in MAI as a result of a recent round of financing. We recognized no unrealized or realized gain or losses d uring the three and nine months ended September 30, 2020. The carrying value of our investment in MAI was $11.5 million and $1.5 million at September 30, 2021 and December 31, 2020, respectively. The carrying value of our investment in Arzeda Corp. was $1.3 million at September 30, 2021. The following table presents balances of the carrying value of non-marketable equity securities (in thousands): September 30, 2021 December 31, 2020 Non-marketable equity securities $ 12,763 $ 1,450

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following tables present the financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands): September 30, 2021 Level 1 Level 2 Level 3 Total Money market funds $ 95,089 $ — $ — $ 95,089 December 31, 2020 Level 1 Level 2 Level 3 Total Money market funds $ 127,567 $ — $ — $ 127,567 Non-marketable debt security — — 1,000 1,000 Total $ 127,567 $ — $ 1,000 $ 128,567 During the three and nine months ended September 30, 2021 and 2020, we did not recognize any significant credit losses nor other-than-temporary impairment losses on non-marketable securities.

Balance Sheets Details

Balance Sheets Details	9 Months Ended
	Sep. 30, 2021
Balance Sheets Details [Abstract]
Balance Sheets Details	Balance Sheets Details Cash Equivalents Cash equivalents as of September 30, 2021 and December 31, 2020, consisted of the following (in thousands): September 30, 2021 December 31, 2020 Adjusted Cost Estimated Fair Value Adjusted Cost Estimated Fair Value Money market funds (1) $ 95,089 $ 95,089 $ 127,567 $ 127,567 (1) Money market funds are classified in cash and cash equivalents on our consolidated balance sheets. Average Contractual Maturities (in days) is not applicable. As of September 30, 2021, the total cash and cash equivalents balance of $119.2 million was comprised of money market funds of $95.1 million and cash of $24.1 million held with major financial institutions. As of December 31, 2020, the total cash and cash equivalents balance of $149.1 million was comprised of money market funds of $127.6 million and cash of $21.5 million held with major financial institutions. Inventories Inventories consisted of the following (in thousands): September 30, 2021 December 31, 2020 Raw materials $ 49 $ 77 Work-in-process 77 82 Finished goods 958 805 Inventories $ 1,084 $ 964 Inventories are recorded net of reserves of $1.5 million as of September 30, 2021 and December 31, 2020. Property and Equipment, net Property and equipment, net consisted of the following (in thousands): September 30, 2021 December 31, 2020 Laboratory equipment $ 29,103 $ 25,468 Leasehold improvements 10,785 10,785 Computer equipment and software 3,313 3,192 Office equipment and furniture 1,247 1,246 Construction in progress 6,678 2,357 Property and equipment 51,126 43,048 Less: accumulated depreciation and amortization (35,002) (33,373) Property and equipment, net $ 16,124 $ 9,675 Depreciation expense included in the Unaudited Condensed Consolidated Statements of Operations was follows (in thousands): Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Depreciation Expense $ 768 $ 503 $ 2,143 $ 1,403 Goodwill Goodwill had a carrying value of $3.2 million as of September 30, 2021 and December 31, 2020. Other Accrued Liabilities Other accrued liabilities consisted of the following (in thousands): September 30, 2021 December 31, 2020 Accrued purchases $ 9,050 $ 7,170 Accrued professional and outside service fees 5,936 2,589 Other 941 513 Total $ 15,927 $ 10,272

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation Equity Incentive Plans In 2019, our board of directors (the "Board") and stockholders approved the 2019 Incentive Award Plan (the "2019 Plan"). The 2019 Plan superseded and replaced in its entirety our 2010 Equity Incentive Plan (the “2010 Plan”) which was effective in March 2010, and no further awards will be granted under the 2010 Plan; however, the terms and conditions of the 2010 Plan will continue to govern any outstanding awards thereunder. The 2019 Plan provides for the grant of stock options, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock awards ("RSAs"), restricted stock units ("RSUs"), performance-contingent restricted stock units ("PSUs"), performance-based options ("PBOs"), other stock or cash-based awards and dividend equivalents to eligible employees and consultants of the Company or any parent or subsidiary, as well as members of the Board. The number of shares of our common stock available for issuance under the 2019 Plan is equal to the sum of (i) 7,897,144 shares, and (ii) any shares subject to awards granted under the 2010 Plan that were outstanding as of April 22, 2019 and thereafter terminate, expire, lapse or are forfeited provided that no more than 14,000,000 shares may be issued upon the exercise of incentive stock options (“ISOs”). In June 2019, 8.1 million shares authorized for issuance under the 2019 Plan were registered under the Securities Act of 1933, as amended (the “Securities Act”). The 2010 Plan provided for the grant of incentive stock options, non-statutory stock options, RSUs, RSAs, PSUs, PBOs, stock appreciation rights, and stock purchase rights to our employees, non-employee directors and consultants. Stock Options The option exercise price for incentive stock options must be at least 100% of the fair value of our common stock on the date of grant and the option exercise price for non-statutory stock options is at least 85% of the fair value of our common stock on the date of grant, as determined by the Board. If, at the time of a grant, the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all of our outstanding capital stock, the exercise price for these options must be at least 110% of the fair value of the underlying common stock. Stock options granted to employees generally have a maximum term of ten years and vest over four years from the date of grant, of which 25% vest at the end of one year, and 75% vest monthly over the remaining three years. We may grant options with different vesting terms from time to time. Unless an employee's termination of service is due to disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of three months or the expiration of the option, whichever is earlier. Restricted Stock Units ("RSUs") We also grant employees RSUs, which generally vest over either a three year period with 33% of the shares subject to the RSUs vesting on each yearly anniversary of the vesting commencement date or over a four year period with 25% of the shares subject to the RSU vesting on each yearly anniversary of the vesting commencement date, in each case contingent upon such employee’s continued service on such vesting date. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. We may grant RSUs with different vesting terms from time to time. Performance-contingent Restricted Stock Units ("PSUs") and Performance Based Options ("PBOs") The compensation committee of the Board approved, solely in respect of non-executive employees, delegated to our Chief Executive Officer the authority to approve grants of PSUs. The compensation committee of the Board also approved grants of PBOs and PSUs to our executives. The PSUs and PBOs vest based upon both the successful achievement of certain corporate operating milestones in specified timelines and continued employment through the applicable vesting date. When the performance goals are deemed to be probable of achievement for these types of awards, recognition of stock-based compensation expense commences. Once the number of shares eligible to vest is determined, those shares vest in two equal installments with 50% vesting upon achievement and the remaining 50% vesting on the first anniversary of achievement, in each case, subject to the recipient’s continued service through the applicable vesting date. If the performance goals are achieved at the threshold level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to half the number of PSUs granted and one-quarter the number of shares underlying the PBOs granted. If the performance goals are achieved at the target level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to the number of PSUs granted and half of the shares underlying the PBOs granted. If the performance goals are achieved at the superior level, the number of shares eligible to vest in respect of the PSUs would be equal to two times the number of PSUs granted and equal to the number of PBOs granted. The number of shares issuable upon achievement of the performance goals at the levels between the threshold and target levels for the PSUs and PBOs or between the target level and superior levels for the PSUs would be determined using linear interpolation. Achievement below the threshold level would result in no shares being eligible to vest in respect of the PSUs and PBOs. In the first quarter of 2021, we awarded PSUs ("2021 PSUs") and PBOs ("2021 PBOs"), each of which commence vesting based upon the achievement of various weighted performance goals, including corporate revenue, performance enzyme segment gross margin, major new biotherapeutics publicity events, strategic performance enzyme and biotherapeutics deliverables, safety, and technology and strategic plan development. As of September 30, 2021, we estimated that the 2021 PSUs and 2021 PBOs performance goals would be achieved at 146% and 73% of the target level, respectively, and recognized stock-based compensation expenses accordingly. In 2020, we awarded PSUs ("2020 PSUs") and PBOs ("2020 PBOs"), each of which commenced vesting based upon the achievement of various weighted performance goals, including corporate revenue, performance enzyme segment gross margin, major new biotherapeutics publicity events, strategic performance enzyme and biotherapeutics deliverables, and strategic plan development. In the first quarter of 2021, we determined that the 2020 PSUs and 2020 PBOs performance goals had been achieved at 88% of the target level, and recognized expenses accordingly. Accordingly, 50% of the shares underlying the 2020 PSUs and PBOs vested in the first quarter of 2021 and 50% of the shares underlying the 2020 PSUs and PBOs will vest in the first quarter of 2022, in each case, subject to the recipient’s continued service on each vesting date. In 2019, we awarded PSUs ("2019 PSUs") and PBOs ("2019 PBOs"), each of which commenced vesting based upon the achievement of various weighted performance goals, including sustained revenue and performance enzyme growth, strategic advancement of biotherapeutics, cash balance and strategic plan development. In the first quarter of 2020, we determined that the 2019 PSUs and 2019 PBOs performance goals had been achieved at 84% of the target level, and recognized expenses accordingly. Accordingly, 50% of the shares underlying the 2019 PSUs and PBOs vested in the first quarter of 2020 and 50% of the shares underlying the 2019 PSUs and PBOs vested in the first quarter of 2021, in each case, subject to the recipient’s continued service on each vesting date. Stock-Based Compensation Expense Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development $ 652 $ 385 $ 1,726 $ 1,279 Selling, general and administrative 2,364 1,599 6,821 4,813 Total $ 3,016 $ 1,984 $ 8,547 $ 6,092 The following table presents total stock-based compensation expense by security type included in the unaudited condensed consolidated statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Stock options $ 693 $ 619 $ 2,040 $ 1,735 RSUs and RSAs 742 603 1,974 1,812 PSUs 640 295 1,683 922 PBOs 941 467 2,850 1,623 Total $ 3,016 $ 1,984 $ 8,547 $ 6,092 As of September 30, 2021 , unrecognized stock-based compensation expense, net of expected forfeitures, was $4.4 million related to unvested stock options, $4.0 million related to unvested RSUs and RSAs, $1.5 million re lated to unvested PSUs, and $2.6 million related to unvested PBOs based on current estimates of the level of achievement. Stock-based compensation ex pense for these awards will be recognized through the year o f 2025.

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Capital Stock	Capital Stock Exercise of Options For the nine months ended September 30, 2021 and 2020, we issued 422,964 and 87,240 shares, respectively, upon option exercises at a weighted-average exercise price of $6.45 and $6.17 per share, respectively, with net cash proceeds of $2.7 million and $0.5 million, respectively. Equity Distribution Agreement We filed a Registration Statement on Form S-3 with the SEC, under which we may sell common stock, preferred stock, debt securities, warrants, purchase contracts, and units from time to time in one or more offerings. The registration statement became effective on May 7, 2021. In May 2021, we entered into an Equity Distribution Agreement ("EDA") with Piper Sandler & Co ("PSC"), under which PSC, as our exclusive agent, at our discretion and at such times that we may determine from time to time, may sell over a three-year period from the execution of the EDA up to a maximum of $50.0 million of shares of our common stock. Under the terms of the EDA, PSC may sell the shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended. We are not required to sell any shares at any time during the term of the EDA. The EDA will terminate upon the earlier of: (i) the issuance and sale of all shares through PSC on the terms and conditions of the EDA, or (ii) the termination of the EDA in accordance with its terms. Either party may terminate the EDA at any time upon written notification to the other party in accordance with the EDA, and upon such notification, the offering will terminate. Under no circumstances shall any shares be sold pursuant to the EDA after the date which is three years after the registration statement is first declared effective by the SEC. We agreed to pay PSC a commission of 3% of the gross sales price of any shares sold pursuant to the EDA. With the exception of certain expenses, we will pay PSC up to 8% of the gross sales price of the shares sold pursuant to the EDA for a combined amount of commission and reimbursement of PSC's expenses and fees.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases Our headquarters are located in Redwood City, California, where we occupy approximately 77,300 square feet of office and laboratory space in multiple buildings within the same business park of Metropolitan Life Insurance Company ("MetLife"). Our lease agreement with MetLife ("RWC Lease") includes approximately 28,200 square feet of space located at 200 and 220 Penobscot Drive, Redwood City, California (the “200/220 Penobscot Space”) and approximately 37,900 square feet of space located at 400 Penobscot Drive, Redwood City, California (the “400 Penobscot Space”) (the 200/220 Penobscot Space and the 400 Penobscot Space are collectively referred to as the “Penobscot Space”), and approximately 11,200 square feet of space located at 501 Chesapeake Drive, Redwood City, California (the “501 Chesapeake Space”). Until the end of January 2020, we also leased approximately 29,900 square feet of space located at 101 Saginaw Drive, Redwood City, California (the “Saginaw Space”). During January 2020, we subleased approximately 26,500 square feet of the Saginaw Space to Minerva Surgical, Inc. The lease and sublease for the Saginaw Space both expired at the end of January 2020. During the period from February 1, 2020 through April 30, 2020, we subleased approximately 3,400 square feet at 101 Saginaw Drive from Minerva Surgical, Inc. The sublease expired at the end of April 2020. We entered into the initial lease with MetLife for our facilities in Redwood City in 2004 and the RWC Lease has been amended multiple times since then to adjust the leased space and terms of the Lease. In February 2019, we entered into an Eighth Amendment to the Lease (the “Eighth Amendment”) with MetLife with respect to the Penobscot Space and the 501 Chesapeake Space to extend the term of the Lease for additional periods. Pursuant to the Eighth Amendment, the term of the lease of the Penobscot Space has been extended through May 2027. The lease term for the 501 Chesapeake Space has been extended to May 2029. We have one (1) option to extend the term of the lease for the Penobscot Space for five (5) years, and one (1) separate option to extend the term of the lease for the 501 Chesapeake Space for five (5) years. We are required to restore certain areas of the Redwood City facilities that we are renting to their original form. We are expensing the asset retirement obligation over the terms of the respective leases. We review the estimated obligation each reporting period and make adjustments if our estimates change. We recorded asset retirement obligations of $0.3 million as of September 30, 2021 and December 31, 2020, which are included in other long-term liabilities in the unaudited condensed consolidated balance sheets. Accretion expense related to our asset retirement obligations was nominal in the three and nine months ended September 30, 2021 and 2020. Pursuant to the terms of the RWC Lease, we exercised our right to deliver a letter of credit in lieu of a security deposit. The letter of credit is collateralized by deposit balances held by the bank in the amount of $1.0 million as of September 30, 2021 and December 31, 2020 and are recorded as non-current restricted cash on the unaudited condensed consolidated balance sheets. We entered into a short-term office lease in San Carlos, California during the second quarter of 2021 and this lease will expire in April 2022. Our remaining future commitment pursuant to this lease is $0.1 million as of September 30, 2021. Finance Leases In December 2016, we entered into a three-year financing lease agreement with a third party supplier for the purchase of laboratory equipment that was partially financed through a finance lease of $0.4 million. The lease became effective upon delivery of the equipment in February 2017, and the term of the three-year lease was from February 2017 and expired in February 2020. This financing agreement was accounted for as a finance lease due to bargain purchase options at the end of the lease. In April 2017, we entered into a three-year financing lease agreement with a third-party supplier for the purchase of information technology equipment for $0.3 million. The effective term of the three-year lease was from May 2017 and expired in April 2020. Lease and other information Lease costs, amounts included in measurement of lease obligations and other information related to non-cancellable operating leases and finance leases were as follows (in thousands): Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Finance lease costs: Amortization of right-of-use assets $ 26 $ 27 $ 79 $ 126 Interest on lease obligations — — — 1 Finance lease costs 26 27 79 127 Operating lease cost 1,032 1,033 3,097 3,133 Short-term lease costs (1) 30 — 40 47 Sublease income — — — (55) Total lease cost (2) $ 1,088 $ 1,060 $ 3,216 $ 3,252 (1 ) Short-term lease costs on leases with terms of over one month and less than one year. (2) The Company had no variable lease costs. Other information: Operating Leases Weighted-average remaining lease term (in years) 5.9 years Weighted-average discount rate 6.6 % Nine months ended September 30, Cash paid: 2021 2020 Operating cash flows from operating leases $ 3,145 $ 1,795 Financing cash flows from finance leases $ — $ 60 As of September 30, 2021, our maturity analysis of annual undiscounted cash flows of the non-cancellable operating leases are as follows (in thousands): Years ending December 31, Operating Leases 2021 (remaining 3 months) $ 1,052 2022 4,285 2023 4,589 2024 4,726 2025 4,868 2026 and thereafter 8,626 Total minimum lease payments 28,146 Less: imputed interest 5,146 Lease obligations $ 23,000 Future Lease Commitment In the first quarter of 2021, we entered into a lease agreement with ARE-San Francisco No. 63, LLC (“ARE”) to lease a portion of a facility comprising approximately 36,593 rentable square feet in San Carlos, California to serve as additional office and research and development laboratory space (the “San Carlos Space”). We expect to commence occupancy of the San Carlos Space in December 2021, once tenant improvements are substantially completed by ARE in accordance with the construction plan. The budget provides a net tenant improvement allowance of $6.3 million and an additional allowance of up to $2.7 million, which we expect to use. ARE will have an enforceable right to payment by us in the form of equal monthly additional rent payments at a certain interest rate through the lease term for the additional allowance. The terms include an initial annualized base rent of $2.5 million, subject to scheduled 3% annual rent increases, an annualized additional allowance payment of $0.4 million, plus certain operating expenses. The lease has a 10-year term from the lease commencement date with one option to extend the term for an additional period of 5 years. We have provided ARE with a $0.5 million security deposit in the form of a letter of credit. We have the right to sublease the facility, subject to landlord consent. We determined that the lease commencement date is in December 2021, at which point we will record a right of use asset and a corresponding operating lease liability. An estimated maturity analysis of the annual undiscounted cash flows of the lease is as follows (in thousands): Years ending December 31, Operating Leases 2021 (remaining 3 months) $ — 2022 2,463 2023 2,988 2024 3,066 2025 3,145 2026 and thereafter 20,061 Total minimum lease payments $ 31,723 Other Commitments We enter into supply and service arrangements in the normal course of business. Supply arrangements are primarily for fixed-price manufacture and supply. Service agreements are primarily for the development of manufacturing processes and certain studies. Commitments under service agreements are subject to cancellation at our discretion which may require payment of certain cancellation fees. The timing of completion of service arrangements is subject to variability in estimates of the time required to complete the work. The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands): Other Commitment Agreement Type Agreement Date Future Minimum Payment Manufacture and supply agreement with expected future payment date of December 2022 April 2016 $ 147 Development and manufacturing services agreements September 2019 686 Total other commitments $ 833 Credit Facility In June 30, 2017, we entered into a credit facility (the “Credit Facility”) with Western Alliance Bank consisting of term loans (“Term Debt”) up to $10.0 million, and advances (“Advances”) under a revolving line of credit ("Revolving Line of Credit") up to $5.0 million with an accounts receivable borrowing base of 80% of eligible accounts receivable. As of September 30, 2021 and December 31, 2020, we have not drawn from the Credit Facility. We may draw on the Term Debt and the Revolving Line of Credit at any time prior to December 31, 2021 and October 1, 2024, respectively. On October 1, 2024 loans drawn under the Term Debt mature and the Revolving Line of Credit terminate. Loans made under the Term Debt bear interest through maturity equal to the greater of (i) 3.75% or (ii) the sum of (A) Index Rate (prime rate published in the Money Rates section of the Western Edition of The Wall Street Journal plus (B) 0.50%. Advances made under the Revolving Line of Credit bear interest at a variable annual rate equal to the equal to the greater of (i) 4.25% or (ii) the sum of (A) the prime rate plus (B) 1.00%. Our obligations under the Credit Facility are secured by a lien on substantially all of our personal property other than our intellectual property. The Credit Facility includes a number of customary covenants and restrictive financial covenants including meeting minimum product revenue levels and maintaining certain minimum cash levels with the lender. The Credit Facility's financial covenants restrict the ability of the Company to transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets, or sell certain assets held at foreign subsidiaries. A failure to comply with these covenants could permit the lender to exercise remedies against us and the collateral securing the Credit Facility, including foreclosure of our properties securing the Credit Facilities and our cash. As of September 30, 2021, we were in compliance with the covenants for the Credit Facility. The Credit Facility allows for interest-only payments on the Term Debt through November 1, 2022. Monthly payments of principal and interest on the Term Debt are required following the applicable amortization date. We may elect to prepay in full the Term Debt and Advances under the Revolving Line of Credit at any time. Legal Proceedings We are not currently a party to any material pending litigation or other material legal proceedings. Indemnifications We are required to recognize a liability for the fair value of any obligations we assume upon the issuance of a guarantee. We have certain agreements with licensors, licensees and collaborators that contain indemnification provisions. In such provisions, we typically agree to indemnify the licensor, licensee and collaborator against certain types of third party claims. The maximum amount of the indemnifications is not limited. We accrue for known indemnification issues when a loss is probable and can be reasonably estimated. There were no accruals for expenses related to indemnification issues for any periods presented.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Molecular Assemblies, Inc. In June 2020, we entered into a Stock Purchase Agreement with MAI pursuant to which we purchased 1,587,050 shares of MAI's Series A preferred stock for $1.0 million. In connection with the transaction, John Nicols, our President and Chief Executive Officer, also joined MAI’s board of directors. Concurrently with our initial equity investment, we entered into the MAI Agreement with MAI, pursuant to which we are performing services utilizing our CodeEvolver ® protein engineering platform technology to improve DNA polymerase enzymes in exchange for compensation in the form of additional shares of MAI's Series A preferred stock. In April 2021, we purchased an additional 1,000,000 shares of MAI's Series A preferred stock for $0.6 million. In September 2021, we purchased 9,198,423 shares of MAI's Series B preferred stock for $7.0 million. We recognized $0.2 million and $0.7 million in research and development revenue from transactions with MAI in the three and nine months ended September 30, 2021, respectively, and we recognized $0.5 million of revenue from research and development service transactions with MAI in the three and nine months ended September 30, 2020. We received 476,114 and 1,904,456 shares of MAI's Series A and B preferred stock from research and development services we provided to MAI in the three and nine months ended September 30, 2021, respectively, and 714,171 shares of MAI's Series A preferred stock from research and development services in the three and nine months ended September 30, 2020. As of September 30, 2021, we have 15,118,271 shares of MAI's Series A and B preferred stock that we have earned or purchased since executing the Stock Purchase Agreement with MAI. The carrying value of our investment in MAI Series A and B preferred stock was $11.5 million and $1.5 million at September 30, 2021 and December 31, 2020, respectively. We had $0.5 million and nil in deferred revenue as of September 30, 2021 and December 31, 2020, respectively, and nil and $0.5 million in contract assets due from MAI for services rendered as of September 30, 2021 and December 31, 2020, respectively. Payment for the services rendered was received in the form of additional MAI Series A and Series B preferred stock. AstraZeneca PLC Pam P. Cheng, who served as a member of our board of directors until June 2020, joined AstraZeneca PLC as Executive Vice President, Operations and Information Technology in June 2015. We sold biocatalyst products to AstraZeneca PLC and its controlled purchasing agents and contract manufacturers. We recogniz ed $0.1 million of revenue in 2020 through the date of Ms. Cheng's departure from our board of directors . As of December 31, 2020, we had no receivables from AstraZeneca PLC and its controlled purchasing agents and contract manufacturers.

Segment, Geographical and Other

Segment, Geographical and Other Revenue Information	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment, Geographical and Other Revenue Information	Segment, Geographical and Other Revenue Information Segment Information We manage our business as two business segments: Performance Enzymes and Novel Biotherapeutics. Our chief operating decision maker ("CODM") is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for the Company. We report corporate-related expenses such as legal, accounting, information technology, and other costs that are not otherwise included in our reportable business segments as "Corporate costs." All items not included in income (loss) from operations are excluded from the business segments. We manage our assets on a total company basis, not by business segment, as the majority of our operating assets are shared or commingled. Our CODM does not review asset information by business segment in assessing performance or allocating resources, and accordingly, we do not report asset information by business segment. Performance Enzymes We initially commercialized our CodeEvolver ® protein engineering technology platform and products in the pharmaceuticals market, and to date this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals. We also use our technology to develop enzymes for customers using NGS and PCR/qPCR for in vitro molecular diagnostic and molecular biology research applications. Novel Biotherapeutics We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver ® protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Most notable is our lead program for the potential treatment of PKU in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. We have also developed a pipeline of other biotherapeutic drug candidates, which are in preclinical development, and in which we expect to continue to make additional investments with the aim of advancing additional product candidates targeting other therapeutic areas. In March 2020, we entered into the Takeda Agreement with Takeda under which we will research and develop protein sequences for use in gene therapy products for certain diseases. Factors considered in determining the two reportable segments of the Company include the nature of business activities, the management structure directly accountable to our CODM for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors. Our CODM regularly reviews our segments and the approach provided by management for performance evaluation and resource allocation. Operating expenses that directly support the segment activity are allocated based on segment headcount, revenue contribution or activity of the business units within the segments, based on the corporate activity type provided to the segment. The expense allocation excludes certain corporate costs that are separately managed from the segments. This provides the CODM with more meaningful segment profitability reporting to support operating decisions and allocate resources. The following table provides financial information by our reportable business segments along with a reconciliation to consolidated income (loss) before income taxes (in thousands): Three months ended September 30, 2021 Three months ended September 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 28,731 $ — $ 28,731 $ 8,401 $ — $ 8,401 Research and development revenue 3,853 4,185 8,038 4,604 5,380 9,984 Total revenues 32,584 4,185 36,769 13,005 5,380 18,385 Costs and operating expenses: Cost of product revenue 6,867 — 6,867 3,642 — 3,642 Research and development (1) 5,670 8,850 14,520 5,184 6,433 11,617 Selling, general and administrative (1) 3,306 831 4,137 2,675 515 3,190 Total segment costs and operating expenses 15,843 9,681 25,524 11,501 6,948 18,449 Income (loss) from operations $ 16,741 $ (5,496) 11,245 $ 1,504 $ (1,568) (64) Corporate costs (2) (8,097) (5,483) Unallocated depreciation and amortization (794) (528) Income (loss) before income taxes $ 2,354 $ (6,075) Nine months ended September 30, 2021 Nine months ended September 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 53,674 $ — $ 53,674 $ 18,005 $ — $ 18,005 Research and development revenue 14,723 11,856 26,579 13,380 16,638 30,018 Total revenues 68,397 11,856 80,253 31,385 16,638 48,023 Costs and operating expenses: Cost of product revenue 15,403 — 15,403 7,882 — 7,882 Research and development (1) 17,172 20,649 37,821 15,877 16,848 32,725 Selling, general and administrative (1) 9,294 2,052 11,346 7,395 1,728 9,123 Total segment costs and operating expenses 41,869 22,701 64,570 31,154 18,576 49,730 Income (loss) from operations $ 26,528 $ (10,845) 15,683 $ 231 $ (1,938) (1,707) Corporate costs (2) (24,431) (16,526) Unallocated depreciation and amortization (2,220) (1,526) Loss before income taxes $ (10,968) $ (19,759) (1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases. (2) Corporate costs include unallocated selling, general and administrative expenses, interest income, and other income (expense), net. The following table provides stock-based compensation expense included in income (loss) from operations (in thousands): Three months ended September 30, 2021 2020 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 1,228 $ 272 $ 1,516 $ 3,016 $ 839 $ 132 $ 1,013 $ 1,984 Nine months ended September 30, 2021 2020 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 3,337 $ 767 $ 4,443 $ 8,547 $ 2,335 $ 625 $ 3,132 $ 6,092 Significant Customers Customers that each accounted for 10% or more of our total revenues were as follows: Percentage of Total Revenues for the Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Customer A 51% * 29% * Customer B * 13% 10% * Customer C * 23% 12% 21% Customer D * 14% * 22% Customer E * 15% * 13% Customer F * * * 11% * Percentage was less than 10% Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows: Percentage of Accounts Receivables as of September 30, 2021 December 31, 2020 Customer A 34% * Customer C 11% 32% Customer E 14% 13% Customer F * 25% * Percentage was less than 10% Geographical Information Geographic revenues are identified by the location of the customer and consist of the following (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Revenues Americas $ 7,816 $ 5,841 $ 18,588 $ 17,972 EMEA 4,685 4,889 17,135 14,175 APAC 24,268 7,655 44,530 15,876 Total revenues $ 36,769 $ 18,385 $ 80,253 $ 48,023 Identifiable long-lived assets by location was as follows (in thousands): September 30, 2021 December 31, 2020 United States $ 35,645 $ 31,176 Identifiable goodwill by reporting unit was as follows (in thousands): As of September 30, 2021 and December 31, 2020 Performance Enzymes Novel Biotherapeutics Total Goodwill $ 2,463 $ 778 $ 3,241

Allowance for Credit Losses

Allowance for Credit Losses	9 Months Ended
	Sep. 30, 2021
Receivables [Abstract]
Allowance for Credit Losses	Allowance for Credit Losses The following table summarizes the financial assets allowance for credit losses (in thousands): September 30, 2021 December 31, 2020 Allowance for credit losses $ 74 $ 74 The following tables summarize accounts receivable by aging category (in thousands): September 30, 2021 Current 31-60 Days 61-90 Days 91 Days and over Total balance Accounts receivable $ 22,328 $ 1,869 $ 847 $ 40 $ 25,084 December 31, 2020 Current 31-60 Days 61-90 Days 91 Days and over Total balance Accounts receivable $ 13,398 $ 489 $ 7 $ — $ 13,894

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying Unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information but does not include all the information and notes required by GAAP for complete financial statements. These interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2020. The condensed consolidated balance sheet at December 31, 2020, has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The significant accounting policies used in preparation of the Unaudited Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2021 and 2020, are consistent with those discussed in Note 2 to the audited consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K and are updated below as necessary. There have been no significant changes in our significant accounting policies or critical accounting estimates since December 31, 2020. Certain prior year amounts have been reclassified in the Unaudited Condensed Statements of Cash Flows to conform to the 2021 presentation, however these reclassifications had no effect on the reported results of operations. The Unaudited Condensed Consolidated Financial Statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly our financial position as of September 30, 2021, results of our operations for the three and nine months ended September 30, 2021 and 2020, changes in stockholders' equity for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020. The interim results are not necessarily indicative of the results for any future interim period or for the entire year.
Use of Estimates	Use of Estimates The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, inventories, valuation of equity investments, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, and may not be accurately predicted, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers, markets and economies.
Accounting Pronouncements	Accounting Pronouncements Recently adopted accounting pronouncements In December 2019, the Financial Accounting Standards Board ("FASB") issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which is intended to simplify various aspects related to accounting for income taxes. We adopted the standard on January 1, 2021, on a modified retrospective basis. The adoption of this standard had no impact on our Unaudited Condensed Consolidated Financial Statements. In October 2020, the FASB issued ASU No. 2020-10, Codification Improvement s. ASU 2020-10 provides amendments to a wide variety of topics in the FASB’s Accounting Standards Codification, which applies to all reporting entities within the scope of the affected accounting guidance. We adopted the standard on January 1, 2021 on a retrospective basis. The adoption of this standard had no impact on our Unaudited Condensed Consolidated Financial Statements. Recently issued accounting pronouncements not yet adopted From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the recently issued standards that are not yet effective will not have a material impact on our Unaudited Condensed Consolidated Financial Statements upon adoption. In May 2021, FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the Emerging Issues Task Force . The standard establishes a principles-based framework in accounting for modifications of freestanding equity-classified written call options on the basis of the economic substance of the underlying transaction. The standard also requires incremental financial statement disclosures. The standard affects entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years with early adoption is permitted by applying the standard as of the beginning of the fiscal year that includes that interim period. The standard may be adopted prospectively for modifications or exchanges occurring on or after the effective date. We will evaluate modifications of equity-classified written call options to determine applicability of the standard on occurrence; however, we believe that the adoption of ASU 2021-04 will have no significant impact on our Unaudited Condensed Consolidated Financial Statements and related disclosures. In August 2020, FASB issued ASU No. 2020-06 Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40) No. 2020-06 August 2020 Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , to reduce the complexity and to simplify the accounting for convertible debt instruments and convertible preferred stock, and the derivatives scope exception for contracts in an entity's own equity. In addition, the guidance on calculating diluted earnings per share has been simplified and made more internally consistent. The standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years with early adoption permitted for fiscal years beginning December 15, 2020. The standard may be adopted on a modified retrospective or fully retrospective method of transition and on adoption, entities may irrevocably elect the fair value option in accordance with Subtopic 825-10, Financial Instruments—Overall, for any financial instrument that is a convertible security. We believe that the adoption of ASU 2020-06 will have no significant impact on our Unaudited Condensed Consolidated Financial Statements and related disclosures. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The standard provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions in which the reference LIBOR or another reference rate are expected to be discontinued as a result of the Reference Rate Reform. The standard is effective for all entities and can be adopted no later than December 1, 2022, with early adoption permitted. The standard may be adopted on a prospective basis. We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to elect optional expedients for contract modification; however, we believe that the adoption of ASU 2020-04 will have no significant impact on our Unaudited Condensed Consolidated Financial Statements and related disclosures. There have been no other recent accounting pronouncements or changes in accounting pronouncements during the three and nine months ended September 30, 2021, as compared to the recent accounting pronouncements described in herein, that are of significance or potential significance to us.
Segment Information	Segment Information We manage our business as two business segments: Performance Enzymes and Novel Biotherapeutics. Our chief operating decision maker ("CODM") is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for the Company. We report corporate-related expenses such as legal, accounting, information technology, and other costs that are not otherwise included in our reportable business segments as "Corporate costs." All items not included in income (loss) from operations are excluded from the business segments.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	Segment information is as follows (in thousands): Three months ended September 30, 2021 Three months ended September 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product revenue $ 28,731 $ — $ 28,731 $ 8,401 $ — $ 8,401 Research and development revenue 3,853 4,185 8,038 4,604 5,380 9,984 Total revenues $ 32,584 $ 4,185 $ 36,769 $ 13,005 $ 5,380 $ 18,385 Primary geographical markets: Americas $ 5,999 $ 1,817 $ 7,816 $ 3,209 $ 2,632 $ 5,841 EMEA 2,317 2,368 4,685 2,141 2,748 4,889 APAC 24,268 — 24,268 7,655 — 7,655 Total revenues $ 32,584 $ 4,185 $ 36,769 $ 13,005 $ 5,380 $ 18,385 Nine months ended September 30, 2021 Nine months ended September 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product revenue $ 53,674 $ — $ 53,674 $ 18,005 $ — $ 18,005 Research and development revenue 14,723 11,856 26,579 13,380 16,638 30,018 Total revenues $ 68,397 $ 11,856 $ 80,253 $ 31,385 $ 16,638 $ 48,023 Primary geographical markets: Americas $ 12,573 $ 6,015 $ 18,588 $ 7,381 $ 10,591 $ 17,972 EMEA 11,294 5,841 17,135 8,128 6,047 14,175 APAC 44,530 — 44,530 15,876 — 15,876 Total revenues $ 68,397 $ 11,856 $ 80,253 $ 31,385 $ 16,638 $ 48,023
Contract with Customer	The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands): September 30, 2021 December 31, 2020 Contract assets $ 12,701 $ 4,526 Unbilled receivables $ 10,760 $ 10,942 Contract costs $ 70 $ 90 Contract liabilities: deferred revenue $ 6,196 $ 4,791 We recognized the following revenues (in thousands): Three months ended September 30, Nine months ended September 30, Revenue recognized in the period for: 2021 2020 2021 2020 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 658 $ 708 $ 1,997 $ 58 Changes in the period: Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods 1,521 233 5,848 854 Performance obligations satisfied from new activities in the period - contract revenue 34,590 17,444 72,408 47,111 Total revenues $ 36,769 $ 18,385 $ 80,253 $ 48,023
Performance Obligation, Expected Timing of Satisfaction	The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2021. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of September 30, 2021 (in thousands): Remainder of 2021 2022 2023 2024 and Thereafter Total Product revenue $ 5 $ 67 $ 67 $ 2,700 $ 2,839 Research and development revenue 1,106 1,705 546 — 3,357 Total revenues $ 1,111 $ 1,772 $ 613 $ 2,700 $ 6,196

Net Income (loss) per Share (Ta

Net Income (loss) per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Income (Loss) Per Share	The following table sets forth the computation of basic and diluted net income (loss) per share during the three and nine months ended September 30, 2021 and 2020 (in thousands, except per share amounts): Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Numerator: Net income (loss) $ 2,244 $ (6,094) $ (11,089) $ (20,090) Denominator: Weighted average common stock shares used in computing net income (loss) per share, basic 64,628 59,061 64,452 58,984 Effect of dilutive shares 3,113 — — — Weighted average common stock shares used in computing net income (loss) per share, diluted 67,741 59,061 64,452 58,984 Net income (loss) per share, basic $ 0.03 $ (0.10) $ (0.17) $ (0.34) Net income (loss) per share, diluted $ 0.03 $ (0.10) $ (0.17) $ (0.34)
Shares Not Included in Computation of Diluted Net (Income) Loss Per Share	The following shares were not considered in the computation of diluted net income (loss) per share because their effect was anti-dilutive (in thousands): Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Shares issuable under the Equity Incentive Plan 451 5,182 5,148 5,182

Investments in Non-Marketable_2

Investments in Non-Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Details of Non-marketable Debt Securities	As of December 31, 2020, the adjusted cost and carrying value and fair value of the non-marketable debt security is the following (in thousands): December 31, 2020 Adjusted Cost and Carrying Value Fair Value Non-marketable debt security due in 1 year or less $ 1,000 $ 1,000
Carrying Value of Non-marketable Equity Securities	The following table presents balances of the carrying value of non-marketable equity securities (in thousands): September 30, 2021 December 31, 2020 Non-marketable equity securities $ 12,763 $ 1,450

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured at Fair Value on a Recurring Basis	The following tables present the financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands): September 30, 2021 Level 1 Level 2 Level 3 Total Money market funds $ 95,089 $ — $ — $ 95,089 December 31, 2020 Level 1 Level 2 Level 3 Total Money market funds $ 127,567 $ — $ — $ 127,567 Non-marketable debt security — — 1,000 1,000 Total $ 127,567 $ — $ 1,000 $ 128,567

Balance Sheets Details (Tables)

Balance Sheets Details (Tables)	9 Months Ended
	Sep. 30, 2021
Balance Sheets Details [Abstract]
Schedule of Cash and Cash Equivalents	Cash equivalents as of September 30, 2021 and December 31, 2020, consisted of the following (in thousands): September 30, 2021 December 31, 2020 Adjusted Cost Estimated Fair Value Adjusted Cost Estimated Fair Value Money market funds (1) $ 95,089 $ 95,089 $ 127,567 $ 127,567 (1) Money market funds are classified in cash and cash equivalents on our consolidated balance sheets. Average Contractual Maturities (in days) is not applicable.
Schedule of Inventory Components	Inventories consisted of the following (in thousands): September 30, 2021 December 31, 2020 Raw materials $ 49 $ 77 Work-in-process 77 82 Finished goods 958 805 Inventories $ 1,084 $ 964
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): September 30, 2021 December 31, 2020 Laboratory equipment $ 29,103 $ 25,468 Leasehold improvements 10,785 10,785 Computer equipment and software 3,313 3,192 Office equipment and furniture 1,247 1,246 Construction in progress 6,678 2,357 Property and equipment 51,126 43,048 Less: accumulated depreciation and amortization (35,002) (33,373) Property and equipment, net $ 16,124 $ 9,675 Depreciation expense included in the Unaudited Condensed Consolidated Statements of Operations was follows (in thousands): Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Depreciation Expense $ 768 $ 503 $ 2,143 $ 1,403
Schedule of Other Accrued Liabilities	Other accrued liabilities consisted of the following (in thousands): September 30, 2021 December 31, 2020 Accrued purchases $ 9,050 $ 7,170 Accrued professional and outside service fees 5,936 2,589 Other 941 513 Total $ 15,927 $ 10,272

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense	Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development $ 652 $ 385 $ 1,726 $ 1,279 Selling, general and administrative 2,364 1,599 6,821 4,813 Total $ 3,016 $ 1,984 $ 8,547 $ 6,092
Schedule of Stock-based Compensation Expense by Security Types	The following table presents total stock-based compensation expense by security type included in the unaudited condensed consolidated statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Stock options $ 693 $ 619 $ 2,040 $ 1,735 RSUs and RSAs 742 603 1,974 1,812 PSUs 640 295 1,683 922 PBOs 941 467 2,850 1,623 Total $ 3,016 $ 1,984 $ 8,547 $ 6,092

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Lease Cost	Lease costs, amounts included in measurement of lease obligations and other information related to non-cancellable operating leases and finance leases were as follows (in thousands): Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Finance lease costs: Amortization of right-of-use assets $ 26 $ 27 $ 79 $ 126 Interest on lease obligations — — — 1 Finance lease costs 26 27 79 127 Operating lease cost 1,032 1,033 3,097 3,133 Short-term lease costs (1) 30 — 40 47 Sublease income — — — (55) Total lease cost (2) $ 1,088 $ 1,060 $ 3,216 $ 3,252 (1 ) Short-term lease costs on leases with terms of over one month and less than one year. (2) The Company had no variable lease costs. Other information: Operating Leases Weighted-average remaining lease term (in years) 5.9 years Weighted-average discount rate 6.6 % Nine months ended September 30, Cash paid: 2021 2020 Operating cash flows from operating leases $ 3,145 $ 1,795 Financing cash flows from finance leases $ — $ 60
Operating Lease Maturity	As of September 30, 2021, our maturity analysis of annual undiscounted cash flows of the non-cancellable operating leases are as follows (in thousands): Years ending December 31, Operating Leases 2021 (remaining 3 months) $ 1,052 2022 4,285 2023 4,589 2024 4,726 2025 4,868 2026 and thereafter 8,626 Total minimum lease payments 28,146 Less: imputed interest 5,146 Lease obligations $ 23,000 An estimated maturity analysis of the annual undiscounted cash flows of the lease is as follows (in thousands): Years ending December 31, Operating Leases 2021 (remaining 3 months) $ — 2022 2,463 2023 2,988 2024 3,066 2025 3,145 2026 and thereafter 20,061 Total minimum lease payments $ 31,723
Schedule of Supply and Service Commitments	The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands): Other Commitment Agreement Type Agreement Date Future Minimum Payment Manufacture and supply agreement with expected future payment date of December 2022 April 2016 $ 147 Development and manufacturing services agreements September 2019 686 Total other commitments $ 833

Segment, Geographical and Oth_2

Segment, Geographical and Other Revenue Information (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting	The following table provides financial information by our reportable business segments along with a reconciliation to consolidated income (loss) before income taxes (in thousands): Three months ended September 30, 2021 Three months ended September 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 28,731 $ — $ 28,731 $ 8,401 $ — $ 8,401 Research and development revenue 3,853 4,185 8,038 4,604 5,380 9,984 Total revenues 32,584 4,185 36,769 13,005 5,380 18,385 Costs and operating expenses: Cost of product revenue 6,867 — 6,867 3,642 — 3,642 Research and development (1) 5,670 8,850 14,520 5,184 6,433 11,617 Selling, general and administrative (1) 3,306 831 4,137 2,675 515 3,190 Total segment costs and operating expenses 15,843 9,681 25,524 11,501 6,948 18,449 Income (loss) from operations $ 16,741 $ (5,496) 11,245 $ 1,504 $ (1,568) (64) Corporate costs (2) (8,097) (5,483) Unallocated depreciation and amortization (794) (528) Income (loss) before income taxes $ 2,354 $ (6,075) Nine months ended September 30, 2021 Nine months ended September 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 53,674 $ — $ 53,674 $ 18,005 $ — $ 18,005 Research and development revenue 14,723 11,856 26,579 13,380 16,638 30,018 Total revenues 68,397 11,856 80,253 31,385 16,638 48,023 Costs and operating expenses: Cost of product revenue 15,403 — 15,403 7,882 — 7,882 Research and development (1) 17,172 20,649 37,821 15,877 16,848 32,725 Selling, general and administrative (1) 9,294 2,052 11,346 7,395 1,728 9,123 Total segment costs and operating expenses 41,869 22,701 64,570 31,154 18,576 49,730 Income (loss) from operations $ 26,528 $ (10,845) 15,683 $ 231 $ (1,938) (1,707) Corporate costs (2) (24,431) (16,526) Unallocated depreciation and amortization (2,220) (1,526) Loss before income taxes $ (10,968) $ (19,759) (1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases. (2) Corporate costs include unallocated selling, general and administrative expenses, interest income, and other income (expense), net. The following table provides stock-based compensation expense included in income (loss) from operations (in thousands): Three months ended September 30, 2021 2020 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 1,228 $ 272 $ 1,516 $ 3,016 $ 839 $ 132 $ 1,013 $ 1,984 Nine months ended September 30, 2021 2020 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 3,337 $ 767 $ 4,443 $ 8,547 $ 2,335 $ 625 $ 3,132 $ 6,092
Schedule of Concentration Risk	Customers that each accounted for 10% or more of our total revenues were as follows: Percentage of Total Revenues for the Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Customer A 51% * 29% * Customer B * 13% 10% * Customer C * 23% 12% 21% Customer D * 14% * 22% Customer E * 15% * 13% Customer F * * * 11% * Percentage was less than 10% Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows: Percentage of Accounts Receivables as of September 30, 2021 December 31, 2020 Customer A 34% * Customer C 11% 32% Customer E 14% 13% Customer F * 25% * Percentage was less than 10%
Schedule of Revenues by Geographical Area	Geographic revenues are identified by the location of the customer and consist of the following (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Revenues Americas $ 7,816 $ 5,841 $ 18,588 $ 17,972 EMEA 4,685 4,889 17,135 14,175 APAC 24,268 7,655 44,530 15,876 Total revenues $ 36,769 $ 18,385 $ 80,253 $ 48,023
Schedule of Long-Lived Assets by Geographical Area	Identifiable long-lived assets by location was as follows (in thousands): September 30, 2021 December 31, 2020 United States $ 35,645 $ 31,176
Schedule of Goodwill	Identifiable goodwill by reporting unit was as follows (in thousands): As of September 30, 2021 and December 31, 2020 Performance Enzymes Novel Biotherapeutics Total Goodwill $ 2,463 $ 778 $ 3,241

Allowance for Credit Losses (Ta

Allowance for Credit Losses (Tables)	9 Months Ended
	Sep. 30, 2021
Receivables [Abstract]
Analysis of Allowance for Credit Losses	The following table summarizes the financial assets allowance for credit losses (in thousands): September 30, 2021 December 31, 2020 Allowance for credit losses $ 74 $ 74
Summary of Accounts Receivable by Aging Category	The following tables summarize accounts receivable by aging category (in thousands): September 30, 2021 Current 31-60 Days 61-90 Days 91 Days and over Total balance Accounts receivable $ 22,328 $ 1,869 $ 847 $ 40 $ 25,084 December 31, 2020 Current 31-60 Days 61-90 Days 91 Days and over Total balance Accounts receivable $ 13,398 $ 489 $ 7 $ — $ 13,894

Description of Business (Detail

Description of Business (Details) - USD ($) $ in Thousands	1 Months Ended				9 Months Ended
	Sep. 30, 2021	Apr. 30, 2021	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to acquire other investments					$ 7,630	$ 1,000
Takeda
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable cash payment				$ 8,500
Molecular Assemblies, Inc. | Series A Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares purchased (in shares)		1,000,000	1,587,050
Payments to acquire other investments		$ 600	$ 1,000
Molecular Assemblies, Inc. | Series B Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares purchased (in shares)	9,198,423				9,198,423
Payments to acquire other investments	$ 7,000

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Total revenues	$ 36,769	$ 18,385	$ 80,253	$ 48,023
Americas
Disaggregation of Revenue [Line Items]
Total revenues	7,816	5,841	18,588	17,972
EMEA
Disaggregation of Revenue [Line Items]
Total revenues	4,685	4,889	17,135	14,175
APAC
Disaggregation of Revenue [Line Items]
Total revenues	24,268	7,655	44,530	15,876
Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	28,731	8,401	53,674	18,005
Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	8,038	9,984	26,579	30,018
Performance Enzymes
Disaggregation of Revenue [Line Items]
Total revenues	32,584	13,005	68,397	31,385
Performance Enzymes | Americas
Disaggregation of Revenue [Line Items]
Total revenues	5,999	3,209	12,573	7,381
Performance Enzymes | EMEA
Disaggregation of Revenue [Line Items]
Total revenues	2,317	2,141	11,294	8,128
Performance Enzymes | APAC
Disaggregation of Revenue [Line Items]
Total revenues	24,268	7,655	44,530	15,876
Performance Enzymes | Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	28,731	8,401	53,674	18,005
Performance Enzymes | Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	3,853	4,604	14,723	13,380
Novel Biotherapeutics
Disaggregation of Revenue [Line Items]
Total revenues	4,185	5,380	11,856	16,638
Novel Biotherapeutics | Americas
Disaggregation of Revenue [Line Items]
Total revenues	1,817	2,632	6,015	10,591
Novel Biotherapeutics | EMEA
Disaggregation of Revenue [Line Items]
Total revenues	2,368	2,748	5,841	6,047
Novel Biotherapeutics | APAC
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics | Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics | Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	$ 4,185	$ 5,380	$ 11,856	$ 16,638

Revenue Recognition - Contracts

Revenue Recognition - Contracts with Customer (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Contract assets	$ 12,701	$ 4,526
Unbilled receivables	10,760	10,942
Contract costs	70	90
Contract liabilities: deferred revenue	$ 6,196	$ 4,791

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Impairment charges related to contract assets	$ 0	$ 0	$ 0	$ 0

Revenue Recognition - Revenue R

Revenue Recognition - Revenue Recognized During Period (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Amounts included in contract liabilities at the beginning of the period:
Performance obligations satisfied	$ 658	$ 708	$ 1,997	$ 58
Changes in the period:
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods	1,521	233	5,848	854
Performance obligations satisfied from new activities in the period - contract revenue	34,590	17,444	72,408	47,111
Total revenues	$ 36,769	$ 18,385	$ 80,253	$ 48,023

Revenue Recognition - Performan

Revenue Recognition - Performance Obligation (Details) $ in Thousands	Sep. 30, 2021USD ($)
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 6,196
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,111
Expected timing of satisfaction, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,772
Expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 613
Expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 2,700
Expected timing of satisfaction, period
Product revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 2,839
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 5
Expected timing of satisfaction, period	3 months
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 67
Expected timing of satisfaction, period	1 year
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 67
Expected timing of satisfaction, period	1 year
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 2,700
Expected timing of satisfaction, period
Research and development revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 3,357
Research and development revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,106
Expected timing of satisfaction, period	3 months
Research and development revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,705
Expected timing of satisfaction, period	1 year
Research and development revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 546
Expected timing of satisfaction, period	1 year
Research and development revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 0
Expected timing of satisfaction, period

Net Income (loss) per Share - E

Net Income (loss) per Share - Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net income (loss)	$ 2,244	$ (6,094)	$ (11,089)	$ (20,090)
Denominator:
Weighted average common stock shares used in computing net income (loss) per share, basic (in shares)	64,628	59,061	64,452	58,984
Effect of dilutive shares (shares)	3,113	0	0	0
Weighted average common stock shares used in computing net income (loss) per share, diluted (in shares)	67,741	59,061	64,452	58,984
Net income (loss) per share, basic (in usd per share)	$ 0.03	$ (0.10)	$ (0.17)	$ (0.34)
Net income (loss) per share, diluted (in usd per share)	$ 0.03	$ (0.10)	$ (0.17)	$ (0.34)

Net Income (loss) per Share - S

Net Income (loss) per Share - Shares Not Included in Computation of Diluted Net Income (Loss) Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Shares issuable under the Equity Incentive Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded as anti-dilutive (in shares)	451	5,182	5,148	5,182

Investments in Non-Marketable_3

Investments in Non-Marketable Securities - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Nov. 30, 2020
Marketable Securities [Line Items]
Investment in non-marketable debt security		$ 0		$ 0		$ 1,000,000
Conversion, debt to equity	$ 1,300,000
Interest income from amortization of discount		0	$ 0	300,000	$ 0
Change in fair value of embedded bifurcated derivative recognized in other income		0
Change in fair value of embedded bifurcated derivative recognized in other expense				10,500
Debt securities, unrealized or realized gains or losses		0	0	0	0
Other expenses			0		0
Upward price adjustment, annual amount			0	700,000	0
Downward price adjustment, annual amount			$ 0		$ 0
Investment in non-marketable equity securities		12,763,000		12,763,000		1,450,000
Molecular Assemblies, Inc.
Marketable Securities [Line Items]
Investment in non-marketable equity securities		11,500,000		11,500,000		1,500,000
Arzeda Corp.
Marketable Securities [Line Items]
Investment in non-marketable equity securities		$ 1,300,000		$ 1,300,000
Series B-2 Preferred Stock
Marketable Securities [Line Items]
Debt conversion, shares issued (in shares)	207,070
Level 3
Marketable Securities [Line Items]
Investment in non-marketable debt security						$ 1,000,000	$ 1,000,000

Investments in Non-Marketable_4

Investments in Non-Marketable Securities - Carrying Value and Fair Value of Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Marketable Securities [Line Items]
Non-marketable debt security due in 1 year or less, Fair Value		$ 1,000
Investment in non-marketable equity securities	$ 12,763	1,450
Level 3
Marketable Securities [Line Items]
Non-marketable debt security due in 1 year or less, Adjusted Cost and Carrying Value		$ 1,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Nov. 30, 2020
Summary of financial instruments measured at fair value on a recurring basis
Non-marketable debt security	$ 0		$ 0		$ 1,000,000
Total					128,567,000
Convertible Debt
Summary of financial instruments measured at fair value on a recurring basis
Credit losses	0	$ 0	0	$ 0
Other-than-temporary impairment losses	0	$ 0	0	$ 0
Money Market Funds
Summary of financial instruments measured at fair value on a recurring basis
Money market funds	95,089,000		95,089,000		127,567,000
Level 1
Summary of financial instruments measured at fair value on a recurring basis
Total					127,567,000
Level 1 | Money Market Funds
Summary of financial instruments measured at fair value on a recurring basis
Money market funds	$ 95,089,000		$ 95,089,000		127,567,000
Level 3
Summary of financial instruments measured at fair value on a recurring basis
Non-marketable debt security					1,000,000	$ 1,000,000
Total					$ 1,000,000

Balance Sheets Details - Cash a

Balance Sheets Details - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020
Cash and Cash Equivalents [Line Items]
Adjusted Cost	$ 119,189	$ 149,117	$ 71,516
Money Market Funds
Cash and Cash Equivalents [Line Items]
Adjusted Cost	95,089	127,567
Estimated Fair Value	95,089	127,567
Cash
Cash and Cash Equivalents [Line Items]
Adjusted Cost	$ 24,100	$ 21,500

Balance Sheets Details - Invent

Balance Sheets Details - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Schedule of Inventory Components
Raw materials	$ 49	$ 77
Work-in-process	77	82
Finished goods	958	805
Inventories	1,084	964
Inventory reserves	$ 1,500	$ 1,500

Balance Sheets Details - Proper

Balance Sheets Details - Property and Equipment, net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment	$ 51,126		$ 51,126		$ 43,048
Less: accumulated depreciation and amortization	(35,002)		(35,002)		(33,373)
Property and equipment, net	16,124		16,124		9,675
Depreciation expense	768	$ 503	2,143	$ 1,403
Laboratory equipment
Property, Plant and Equipment [Line Items]
Property and equipment	29,103		29,103		25,468
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment	10,785		10,785		10,785
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment	3,313		3,313		3,192
Office equipment and furniture
Property, Plant and Equipment [Line Items]
Property and equipment	1,247		1,247		1,246
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment	$ 6,678		$ 6,678		$ 2,357

Balance Sheets Details - Goodwi

Balance Sheets Details - Goodwill (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Balance Sheets Details [Abstract]
Goodwill	$ 3,241	$ 3,241

Balance Sheets Details - Other

Balance Sheets Details - Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Balance Sheets Details [Abstract]
Accrued purchases	$ 9,050	$ 7,170
Accrued professional and outside service fees	5,936	2,589
Other	941	513
Total	$ 15,927	$ 10,272

Stock-based Compensation - Equi

Stock-based Compensation - Equity Incentive Plans (Details) - 2019 Plan - shares	Jun. 30, 2019	Apr. 22, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)		7,897,144
Maximum number of shares to be issued upon exercise of stock options (in shares)		14,000,000
Number of shares authorized (in shares)	8,100,000

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Options (Details)	9 Months Ended
	Sep. 30, 2021
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock	100.00%
Non-Statutory Stock Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock	85.00%
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of voting interests	10.00%
Purchase price of common stock above minimum threshold	110.00%
Award vesting period	4 years
Expiration period of options upon employee's termination of service	3 months
Stock Options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Stock Options | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights percentage	25.00%
Stock Options | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights percentage	75.00%

Stock-based Compensation - Rest

Stock-based Compensation - Restricted Stock Units (Details) - RSUs	9 Months Ended
	Sep. 30, 2021
Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Award vesting rights percentage	33.00%
Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Award vesting rights percentage	25.00%

Stock-based Compensation - PSUs

Stock-based Compensation - PSUs and PBOs (Details) - Performance Shares - installment	3 Months Ended			9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of installments				2
Performance awards, threshold level, number of shares, multiplier				0
Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights percentage				50.00%
Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights percentage				50.00%
2021 PSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate				146.00%
2020 PBO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate				73.00%
2020 PSU and PBO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate		88.00%
2020 PSU and PBO | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights percentage		50.00%
2020 PSU and PBO | Tranche Two | Forecast
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights percentage	50.00%
2019 PSU and PBO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate			84.00%
2019 PSU and PBO | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights percentage			50.00%
2019 PSU and PBO | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights percentage		50.00%

Stock-based Compensation - St_2

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 3,016	$ 1,984	$ 8,547	$ 6,092
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	693	619	2,040	1,735
Compensation not yet recognized, stock options	4,400		4,400
RSUs and RSAs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	742	603	1,974	1,812
Compensation not yet recognized, share-based awards other than options	4,000		4,000
PSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	640	295	1,683	922
Compensation not yet recognized, share-based awards other than options	1,500		1,500
PBOs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	941	467	2,850	1,623
Compensation not yet recognized, share-based awards other than options	2,600		2,600
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	652	385	1,726	1,279
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 2,364	$ 1,599	$ 6,821	$ 4,813

Capital Stock (Details)

Capital Stock (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	May 31, 2021	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Subsidiary, Sale of Stock [Line Items]
Stock options exercised (in shares)			422,964	87,240
Weighted average exercise price of stock options exercised (usd per share)			$ 6.45	$ 6.17
Proceeds from exercises of stock options			$ 2,700,000	$ 539,000
PSC
Subsidiary, Sale of Stock [Line Items]
Sale period	3 years
Value of shares for issuance		$ 50,000,000	$ 50,000,000
Commissions as percentage of gross sales price	3.00%
Shares issued (in shares)		0	0
PSC | Maximum
Subsidiary, Sale of Stock [Line Items]
Value of shares for issuance	$ 50,000,000
Commissions and reimbursements of expenses as percentage of gross sales price	8.00%

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details)	Jun. 30, 2017USD ($)	Apr. 30, 2017USD ($)	Dec. 31, 2016USD ($)	Mar. 31, 2021USD ($)ft²reportingUnit	Sep. 30, 2021USD ($)ft²renewalOption	Dec. 31, 2020USD ($)	Apr. 30, 2020ft²	Jan. 31, 2020ft²	Feb. 28, 2017
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²					77,300
Number of options to extend | renewalOption					1
Asset retirement obligations					$ 300,000	$ 300,000
Future lease commitment					28,146,000
Term of contract		3 years	3 years						3 years
Capital lease obligations incurred		$ 300,000	$ 400,000
Percentage of eligible accounts receivable	80.00%
Indemnification Agreement
Commitments and Contingencies [Line Items]
Loss contingency accrual					0
Term Loan
Commitments and Contingencies [Line Items]
Borrowing capacity	$ 10,000,000
Stated interest rate	3.75%
Basis spread on variable rate (percent)	0.50%
Revolving Credit Facility
Commitments and Contingencies [Line Items]
Borrowing capacity	$ 5,000,000
Stated interest rate	4.25%
Basis spread on variable rate (percent)	1.00%
San Carlos, Califiornia
Commitments and Contingencies [Line Items]
Future lease commitment					100,000
Demand Deposits
Commitments and Contingencies [Line Items]
Non-current restricted cash					$ 1,000,000	$ 1,000,000
200-220 Penobscot
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²					28,200
400 Penobscot
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²					37,900
Renewal term					5 years
501 Chesapeake
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²					11,200
Number of options to extend | renewalOption					1
Renewal term					5 years
101 Saginaw
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²								29,900
Sublease
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²							3,400	26,500
San Carlos
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²				36,593
Number of options to extend | reportingUnit				1
Future lease commitment					$ 31,723,000
Annualized rent				$ 2,500,000
Annual rent increases (as a percent)				3.00%
Lease term				10 years
Renewal term				5 years
Security deposit				$ 500,000
San Carlos | Leaseholds and Leasehold Improvements
Commitments and Contingencies [Line Items]
Tenant improvement allowance				6,300,000
San Carlos | Asset under Construction
Commitments and Contingencies [Line Items]
Tenant improvement allowance				2,700,000
Annualized rent				$ 400,000

Commitments and Contingencies_2

Commitments and Contingencies - Lease Cost (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Schedule of Commitments and Contingencies [Line Items]
Amortization of right-of-use assets	$ 26,000	$ 27,000	$ 79,000	$ 126,000
Interest on lease obligations	0	0	0	1,000
Finance lease costs	26,000	27,000	79,000	127,000
Operating lease cost	1,032,000	1,033,000	3,097,000	3,133,000
Short-term lease costs	30,000	0	40,000	47,000
Sublease income	0	0	0	(55,000)
Total lease cost	1,088,000	1,060,000	3,216,000	3,252,000
Variable lease cost	$ 0	$ 0	$ 0	$ 0
Minimum
Schedule of Commitments and Contingencies [Line Items]
Short-term lease, term			1 month
Maximum
Schedule of Commitments and Contingencies [Line Items]
Short-term lease, term			1 year

Commitments and Contingencies_3

Commitments and Contingencies - Other Lease Information (Details)	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Weighted-average remaining lease term	5 years 10 months 24 days
Weighted-average discount rate	6.60%

Commitments and Contingencies_4

Commitments and Contingencies - Cash Paid for Lease Obligations (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Operating cash flows from operating leases	$ 3,145	$ 1,795
Financing cash flows from finance leases	$ 0	$ 60

Commitments and Contingencies_5

Commitments and Contingencies - Maturity Analysis of Operating Lease (Details) $ in Thousands	Sep. 30, 2021USD ($)
Operating Leases
2021 (remaining 3 months)	$ 1,052
2022	4,285
2023	4,589
2024	4,726
2025	4,868
2026 and thereafter	8,626
Total minimum lease payments	28,146
Less: imputed interest	5,146
Lease obligations	$ 23,000

Commitments and Contingencies_6

Commitments and Contingencies - Estimated Maturity Analysis (Details) $ in Thousands	Sep. 30, 2021USD ($)
Operating Leases
2021 (remaining 3 months)	$ 1,052
2022	4,285
2023	4,589
2024	4,726
2025	4,868
2026 and thereafter	8,626
Total minimum lease payments	28,146
San Carlos
Operating Leases
2021 (remaining 3 months)	0
2022	2,463
2023	2,988
2024	3,066
2025	3,145
2026 and thereafter	20,061
Total minimum lease payments	$ 31,723

Commitments and Contingencies_7

Commitments and Contingencies - Other Commitments (Details) - Supply Commitment $ in Thousands	Sep. 30, 2021USD ($)
Other Commitments [Line Items]
Future Minimum Payment	$ 833
April 2016
Other Commitments [Line Items]
Future Minimum Payment	147
September 2019
Other Commitments [Line Items]
Future Minimum Payment	$ 686

Related Party Transactions - Mo

Related Party Transactions - Molecular Assemblies, Inc. (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2021	Apr. 30, 2021	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Related Party Transaction [Line Items]
Payments to acquire other investments							$ 7,630,000	$ 1,000,000
Investment at cost basis	$ 12,763,000	$ 12,763,000			$ 12,763,000		12,763,000		$ 1,450,000
Deferred revenue	6,196,000	6,196,000			6,196,000		6,196,000		4,791,000
Contract assets	12,701,000	12,701,000			12,701,000		12,701,000		4,526,000
Molecular Assemblies, Inc.
Related Party Transaction [Line Items]
Deferred revenue	500,000	500,000			500,000		500,000		0
Contract assets	0	0			0		0		500,000
Molecular Assemblies, Inc. | MCRA
Related Party Transaction [Line Items]
Research and development revenue from transactions with MAI					200,000	$ 500,000	700,000	$ 500,000
Series A Preferred Stock
Related Party Transaction [Line Items]
Investment at cost basis	$ 11,500,000	11,500,000			$ 11,500,000		$ 11,500,000		1,500,000
Series A Preferred Stock | Molecular Assemblies, Inc. | MCRA
Related Party Transaction [Line Items]
Number of shares received in exchange for services (in shares)					476,114	714,171	1,904,456	714,171
Number of shares received in exchange for services (in shares)	15,118,271
Series B Preferred Stock
Related Party Transaction [Line Items]
Investment at cost basis	$ 11,500,000	$ 11,500,000			$ 11,500,000		$ 11,500,000		$ 1,500,000
Series B Preferred Stock | Molecular Assemblies, Inc. | MCRA
Related Party Transaction [Line Items]
Number of shares received in exchange for services (in shares)					476,114		1,904,456
Number of shares received in exchange for services (in shares)	15,118,271
Molecular Assemblies, Inc. | Series A Preferred Stock
Related Party Transaction [Line Items]
Number of shares purchased (in shares)			1,000,000	1,587,050
Payments to acquire other investments			$ 600,000	$ 1,000,000
Molecular Assemblies, Inc. | Series B Preferred Stock
Related Party Transaction [Line Items]
Number of shares purchased (in shares)	9,198,423	9,198,423			9,198,423		9,198,423
Payments to acquire other investments		$ 7,000,000

Related Party Transactions - As

Related Party Transactions - AstraZeneca PLC (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2020
Related Party Transaction [Line Items]
Accounts receivable from related parties		$ 0
Director | Transactions with AstraZeneca PLC
Related Party Transaction [Line Items]
Revenue from related parties	$ 100,000

Segment, Geographical and Oth_3

Segment, Geographical and Other Revenue Information - Narrative (Details)	9 Months Ended
	Sep. 30, 2021segment
Segment Reporting [Abstract]
Number of operating segments	2
Number of reportable segments	2

Segment, Geographical and Oth_4

Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Total revenues	$ 36,769	$ 18,385	$ 80,253	$ 48,023
Cost of product revenue	6,867	3,642	15,403	7,882
Research and development	15,165	12,010	39,562	33,830
Selling, general and administrative	13,407	8,797	37,600	26,307
Total costs and operating expenses	35,439	24,449	92,565	68,019
Income (loss) from operations	1,330	(6,064)	(12,312)	(19,996)
Unallocated depreciation and amortization	(768)	(503)	(2,143)	(1,403)
Stock-based compensation	3,016	1,984	8,547	6,092
Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	32,584	13,005	68,397	31,385
Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	4,185	5,380	11,856	16,638
Product revenue
Segment Reporting Information [Line Items]
Total revenues	28,731	8,401	53,674	18,005
Product revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	28,731	8,401	53,674	18,005
Product revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	8,038	9,984	26,579	30,018
Research and development revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	3,853	4,604	14,723	13,380
Research and development revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	4,185	5,380	11,856	16,638
Operating segments
Segment Reporting Information [Line Items]
Total revenues	36,769	18,385	80,253	48,023
Cost of product revenue	6,867	3,642	15,403	7,882
Research and development	14,520	11,617	37,821	32,725
Selling, general and administrative	4,137	3,190	11,346	9,123
Total costs and operating expenses	25,524	18,449	64,570	49,730
Income (loss) from operations	11,245	(64)	15,683	(1,707)
Stock-based compensation	3,016	1,984	8,547	6,092
Operating segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	32,584	13,005	68,397	31,385
Cost of product revenue	6,867	3,642	15,403	7,882
Research and development	5,670	5,184	17,172	15,877
Selling, general and administrative	3,306	2,675	9,294	7,395
Total costs and operating expenses	15,843	11,501	41,869	31,154
Income (loss) from operations	16,741	1,504	26,528	231
Stock-based compensation	1,228	839	3,337	2,335
Operating segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	4,185	5,380	11,856	16,638
Cost of product revenue	0	0	0	0
Research and development	8,850	6,433	20,649	16,848
Selling, general and administrative	831	515	2,052	1,728
Total costs and operating expenses	9,681	6,948	22,701	18,576
Income (loss) from operations	(5,496)	(1,568)	(10,845)	(1,938)
Stock-based compensation	272	132	767	625
Operating segments | Product revenue
Segment Reporting Information [Line Items]
Total revenues	28,731	8,401	53,674	18,005
Operating segments | Product revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	28,731	8,401
Operating segments | Product revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0
Operating segments | Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	8,038	9,984	26,579	30,018
Operating segments | Research and development revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	3,853	4,604
Operating segments | Research and development revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	4,185	5,380
Corporate, non-segment
Segment Reporting Information [Line Items]
Total costs and operating expenses	(8,097)	(5,483)	(24,431)	(16,526)
Unallocated depreciation and amortization	(794)	(528)	(2,220)	(1,526)
Income (loss) before income taxes	2,354	(6,075)	(10,968)	(19,759)
Stock-based compensation	$ 1,516	$ 1,013	$ 4,443	$ 3,132

Segment, Geographical and Oth_5

Segment, Geographical and Other Revenue Information - Concentration Risk (Details) - Customer Concentration Risk	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Revenue, Product and Service Benchmark | Customer A
Concentration Risk [Line Items]
Concentration risk	51.00%		29.00%
Revenue, Product and Service Benchmark | Customer B
Concentration Risk [Line Items]
Concentration risk		13.00%	10.00%
Revenue, Product and Service Benchmark | Customer C
Concentration Risk [Line Items]
Concentration risk		23.00%	12.00%	21.00%
Revenue, Product and Service Benchmark | Customer D
Concentration Risk [Line Items]
Concentration risk		14.00%		22.00%
Revenue, Product and Service Benchmark | Customer E
Concentration Risk [Line Items]
Concentration risk		15.00%		13.00%
Revenue, Product and Service Benchmark | Customer F
Concentration Risk [Line Items]
Concentration risk				11.00%
Accounts Receivable | Customer A
Concentration Risk [Line Items]
Concentration risk			34.00%
Accounts Receivable | Customer C
Concentration Risk [Line Items]
Concentration risk			11.00%		32.00%
Accounts Receivable | Customer E
Concentration Risk [Line Items]
Concentration risk			14.00%		13.00%
Accounts Receivable | Customer F
Concentration Risk [Line Items]
Concentration risk					25.00%

Segment, Geographical and Oth_6

Segment, Geographical and Other Revenue Information - Revenues by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Total revenues	$ 36,769	$ 18,385	$ 80,253	$ 48,023
Americas
Segment Reporting Information [Line Items]
Total revenues	7,816	5,841	18,588	17,972
EMEA
Segment Reporting Information [Line Items]
Total revenues	4,685	4,889	17,135	14,175
APAC
Segment Reporting Information [Line Items]
Total revenues	$ 24,268	$ 7,655	$ 44,530	$ 15,876

Segment, Geographical and Oth_7

Segment, Geographical and Other Revenue Information - Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
United States
Geographic Areas, Long-Lived Assets [Abstract]
Long-lived assets	$ 35,645	$ 31,176

Segment, Geographical and Oth_8

Segment, Geographical and Other Revenue Information - Goodwill (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Goodwill	$ 3,241	$ 3,241
Operating Segments
Segment Reporting Information [Line Items]
Goodwill	3,241	3,241
Operating Segments | Performance Enzymes
Segment Reporting Information [Line Items]
Goodwill	2,463	2,463
Operating Segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Goodwill	$ 778	$ 778

Allowance for Credit Losses - A

Allowance for Credit Losses - Analysis of Allowance for Credit Losses (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Receivables [Abstract]
Allowance for credit losses	$ 74	$ 74

Allowance for Credit Losses - S

Allowance for Credit Losses - Summary of Finance Receivables by Aging Category (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	$ 25,084	$ 13,894
Current
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	22,328	13,398
31-60 Days
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	1,869	489
61-90 Days
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	847	7
91 Days and over
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	$ 40	$ 0